Galanis, Evanthia <br/><br/>
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.  [electronic resource] 

 -  Cancer research  Feb 2010 
 - 875-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-09-2762  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--etiology<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Carcinoembryonic Antigen--genetics<br/>Chlorocebus aethiops<br/>Fatigue--etiology<br/>Female<br/>Fever--etiology<br/>Humans<br/>Injections, Intraperitoneal<br/>Measles virus--genetics<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Oncolytic Virotherapy--adverse effects<br/>Oncolytic Viruses--genetics<br/>Ovarian Neoplasms--pathology<br/>Recombinant Fusion Proteins--administration & dosage<br/>Treatment Outcome<br/>Vero Cells